Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue
13 janv. 2025 07h00 HE
|
Axsome Therapeutics, Inc.
Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi preliminary 4Q and full year 2024 net product revenue of $25.7 million and $93.8...
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
30 déc. 2024 07h00 HE
|
Axsome Therapeutics, Inc.
ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared to...
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
26 nov. 2024 07h00 HE
|
Axsome Therapeutics, Inc.
AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) Statistically significant improvement in cognition compared to placebo...
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
12 nov. 2024 07h00 HE
|
Axsome Therapeutics, Inc.
Total 3Q 2024 net product revenue of $104.8 million, representing 81% year-over-year growth Auvelity® 3Q 2024 net product sales of $80.4 million, representing 113% year-over-year growth Sunosi® 3Q...
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
08 nov. 2024 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
29 oct. 2024 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
15 oct. 2024 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
24 sept. 2024 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
04 sept. 2024 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Participate in Investor Conferences in September
27 août 2024 07h00 HE
|
Axsome Therapeutics, Inc.
Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York Wells Fargo Healthcare Conference on September 5 in Boston Baird 2024 Global Healthcare Conference on September...